论文信息 - Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial - 字舞流文

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial

F. Brunetti | A. Lièvre | C. Lepage | G. Piessen | O. Bouché | J. Regimbeau | J. Taieb | M. Prudhomme | O. Glehen | G. Portier | C. Lécaille | M. Karoui | B. Romain | C. de Chaisemartin | J. Legoux | G. Goujon | E. Barbier | C. Gallois | H. Ammarguellat | J. Hartwig